Insmed, Inc. (INSM) — 分析摘要
Insmed, Inc.（INSM）的市值为23.66十亿美元，最近一年的营收同比增长了+66.7%。净利润率为-210.5%。当前市盈率为-20.0倍。
核心要点
- 营收同比变化+66.7%
- 净利润率-210.5%
- 市盈率-20.0倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，INSM的营收增长为+66.7%，市盈率为-20.0倍。
Insmed, Inc. (INSM)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -14.0x — 盈利不足以覆盖利息支出
营业利润率为 -140.6% — 严重经营亏损
净利率为 -144.4% — 亏损超过收入（可能含一次性费用）
最新报表显示自由现金流为负。
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
1,664
总部
BRIDGEWATER, NJ
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。